Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- S&P 500, Nasdaq end lower as crude prices jump, chip stocks weigh
- Oil rises 4% on revived Middle East worries, Hurricane Isaias supply disruption
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 62.01 +0.89 (1.46%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $61.12 | 52 Week High | $13.18 | |||
| Open | $60.31 | 52 Week Low | $6.00 | |||
| Day High | $62.79 | P/E | N/A | |||
| Day Low | $59.79 | EPS | $-1.24 | |||
| Volume | 2,594,636 | |||||
| REPROS THERAPEUTICS (NASDAQ: RPRX) | Delayed: 56.21 -0.55 (0.97%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $56.76 | 52 Week High | $3.48 | |||
| Open | $56.57 | 52 Week Low | $0.80 | |||
| Day High | $56.71 | P/E | N/A | |||
| Day Low | $55.13 | EPS | $-1.54 | |||
| Volume | 2,847,238 | |||||
